India, March 21 -- The company said it is the first Indian pharmaceutical firm to receive approval from the Drugs Controller General of India (DCGI) for generic semaglutide, enabling a day-one launch upon patent expiry. It added that the move reflects its readiness to serve unmet patient needs in India. India faces one of the world's largest diabetes burdens, with over 101 million adults living with the condition, according to the ICMR INDIAB study. The study estimates diabetes prevalence at 11.4%, with nearly four in ten adults experiencing abdominal obesity. An additional 136 million individuals are estimated to be pre diabetic, placing them at high risk of developing the disease. In such a scenario, semaglutide, a GLP 1 receptor agonis...